369 related articles for article (PubMed ID: 33006762)
1. The pursuit of precision mitochondrial medicine: Harnessing preclinical cellular and animal models to optimize mitochondrial disease therapeutic discovery.
Falk MJ
J Inherit Metab Dis; 2021 Mar; 44(2):312-324. PubMed ID: 33006762
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic modeling of primary mitochondrial respiratory chain dysfunction in zebrafish.
Byrnes J; Ganetzky R; Lightfoot R; Tzeng M; Nakamaru-Ogiso E; Seiler C; Falk MJ
Neurochem Int; 2018 Jul; 117():23-34. PubMed ID: 28732770
[TBL] [Abstract][Full Text] [Related]
3. N-acetylcysteine and vitamin E rescue animal longevity and cellular oxidative stress in pre-clinical models of mitochondrial complex I disease.
Polyak E; Ostrovsky J; Peng M; Dingley SD; Tsukikawa M; Kwon YJ; McCormack SE; Bennett M; Xiao R; Seiler C; Zhang Z; Falk MJ
Mol Genet Metab; 2018 Apr; 123(4):449-462. PubMed ID: 29526616
[TBL] [Abstract][Full Text] [Related]
4. Dichloroacetate improves mitochondrial function, physiology, and morphology in FBXL4 disease models.
Lavorato M; Nakamaru-Ogiso E; Mathew ND; Herman E; Shah N; Haroon S; Xiao R; Seiler C; Falk MJ
JCI Insight; 2022 Aug; 7(16):. PubMed ID: 35881484
[TBL] [Abstract][Full Text] [Related]
5. Combinatorial glucose, nicotinic acid and N-acetylcysteine therapy has synergistic effect in preclinical C. elegans and zebrafish models of mitochondrial complex I disease.
Guha S; Mathew ND; Konkwo C; Ostrovsky J; Kwon YJ; Polyak E; Seiler C; Bennett M; Xiao R; Zhang Z; Nakamaru-Ogiso E; Falk MJ
Hum Mol Genet; 2021 May; 30(7):536-551. PubMed ID: 33640978
[TBL] [Abstract][Full Text] [Related]
6. The mitochondria-targeted hydrogen sulfide donor AP39 improves health and mitochondrial function in a C. elegans primary mitochondrial disease model.
Fox BC; Slade L; Torregrossa R; Pacitti D; Szabo C; Etheridge T; Whiteman M
J Inherit Metab Dis; 2021 Mar; 44(2):367-375. PubMed ID: 33325042
[TBL] [Abstract][Full Text] [Related]
7. Pre-clinical evaluation of cysteamine bitartrate as a therapeutic agent for mitochondrial respiratory chain disease.
Guha S; Konkwo C; Lavorato M; Mathew ND; Peng M; Ostrovsky J; Kwon YJ; Polyak E; Lightfoot R; Seiler C; Xiao R; Bennett M; Zhang Z; Nakamaru-Ogiso E; Falk MJ
Hum Mol Genet; 2019 Jun; 28(11):1837-1852. PubMed ID: 30668749
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial biogenesis: pharmacological approaches.
Valero T
Curr Pharm Des; 2014; 20(35):5507-9. PubMed ID: 24606795
[TBL] [Abstract][Full Text] [Related]
9. Comparative Analysis of Experimental Methods to Quantify Animal Activity in Caenorhabditis elegans Models of Mitochondrial Disease.
Lavorato M; Mathew ND; Shah N; Nakamaru-Ogiso E; Falk MJ
J Vis Exp; 2021 Apr; (170):. PubMed ID: 33871460
[TBL] [Abstract][Full Text] [Related]
10. New Developments in CRISPR/Cas-based Functional Genomics and their Implications for Research Using Zebrafish.
Prykhozhij SV; Caceres L; Berman JN
Curr Gene Ther; 2017; 17(4):286-300. PubMed ID: 29173171
[TBL] [Abstract][Full Text] [Related]
11. Identification of drug modifiers for RYR1-related myopathy using a multi-species discovery pipeline.
Volpatti JR; Endo Y; Knox J; Groom L; Brennan S; Noche R; Zuercher WJ; Roy P; Dirksen RT; Dowling JJ
Elife; 2020 Mar; 9():. PubMed ID: 32223895
[TBL] [Abstract][Full Text] [Related]
12. Early developmental expression of Mus musculus zinc finger RNA-binding protein compared to orthologs in Caenorhabditis elegans and Danio rerio and subcellular localization of Mus musculus and Caenorhabditis elegans zinc finger RNA-binding protein in 2-cell Mus musculus embryos.
Doğanlı C; Kjærgaard T; Olsen A; Oxvig C; Füchtbauer EM; Lykke-Hartmann K
DNA Cell Biol; 2010 Dec; 29(12):713-27. PubMed ID: 21091219
[TBL] [Abstract][Full Text] [Related]
13. 8-year retrospective analysis of intravenous arginine therapy for acute metabolic strokes in pediatric mitochondrial disease.
Ganetzky RD; Falk MJ
Mol Genet Metab; 2018 Mar; 123(3):301-308. PubMed ID: 29428506
[TBL] [Abstract][Full Text] [Related]
14. New tools for old drugs: Functional genetic screens to optimize current chemotherapy.
Gerhards NM; Rottenberg S
Drug Resist Updat; 2018 Jan; 36():30-46. PubMed ID: 29499836
[TBL] [Abstract][Full Text] [Related]
15. An automated phenotype-based microscopy screen to identify pro-longevity interventions acting through mitochondria in C. elegans.
Maglioni S; Arsalan N; Franchi L; Hurd A; Opipari AW; Glick GD; Ventura N
Biochim Biophys Acta; 2015 Nov; 1847(11):1469-78. PubMed ID: 25979236
[TBL] [Abstract][Full Text] [Related]
16. Metabolic pathway profiling of mitochondrial respiratory chain mutants in C. elegans.
Falk MJ; Zhang Z; Rosenjack JR; Nissim I; Daikhin E; Nissim I; Sedensky MM; Yudkoff M; Morgan PG
Mol Genet Metab; 2008 Apr; 93(4):388-97. PubMed ID: 18178500
[TBL] [Abstract][Full Text] [Related]
17. Concise Review: Induced Pluripotent Stem Cell-Based Drug Discovery for Mitochondrial Disease.
Inak G; Lorenz C; Lisowski P; Zink A; Mlody B; Prigione A
Stem Cells; 2017 Jul; 35(7):1655-1662. PubMed ID: 28544378
[TBL] [Abstract][Full Text] [Related]
18. Cellular and molecular modifier pathways in tauopathies: the big picture from screening invertebrate models.
Hannan SB; Dräger NM; Rasse TM; Voigt A; Jahn TR
J Neurochem; 2016 Apr; 137(1):12-25. PubMed ID: 26756400
[TBL] [Abstract][Full Text] [Related]
19. Mitochondrial medicine therapies: rationale, evidence, and dosing guidelines.
Barcelos I; Shadiack E; Ganetzky RD; Falk MJ
Curr Opin Pediatr; 2020 Dec; 32(6):707-718. PubMed ID: 33105273
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
